Beactica Therapeutics is a specialist precision oncology company, founded in 2006 as a spin-out from Uppsala University in Sweden.
With a precise and targeted approach, we bring highly accomplished specialists and our rich history in drug discovery & development together to methodically fulfil urgent needs within the cancer therapeutics industry.
Investing in Beactica offers a compelling opportunity to build wealth in proprietary small molecule cancer therapeutics, building on the company’s established track record and partner-validated drug development technology.
Beactica Therapeutics' CEO, Dr Per Källblad, briefly presents the investment opportunity connected to the company's transition into a clinical-stage company.
Check out our latest innovations and news here.
The Company’s legal trading name is Beactica Therapeutics AB
The Company was founded in 2006 by Dr Per Källblad and Prof. Helena Danielson.
The Company is privately held.
The Company is headquartered in Uppsala, Sweden. Click here for Company contact information.
The Company is incorporated in Sweden.
The Company’s independent auditor is PwC. They have had this role since Beactica was founded in 2006.
The Company’s legal counsel is Lindahl. Beactica has worked with Lindahl since 2006.
The Company’s bank is Nordea Bank.
The Company’s intellectual property (IP) advisor is AWA.
Keep up to date with the events we will be attending on our events page .
Please email firstname.lastname@example.org for all investor inquiries.
Sign up for the Beactica newsletter to receive our latest news and updates